

Johannes Witjes

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7209353/publications.pdf>

Version: 2024-02-01

180
papers

15,874
citations

26630

56
h-index

17592

121
g-index

186
all docs

186
docs citations

186
times ranked

11504
citing authors

#	ARTICLE	IF	CITATIONS
1	Predicting Recurrence and Progression in Individual Patients with Stage Ta T1 Bladder Cancer Using EORTC Risk Tables: A Combined Analysis of 2596 Patients from Seven EORTC Trials. <i>European Urology</i> , 2006, 49, 466-477.	1.9	2,360
2	Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer. <i>European Urology</i> , 2017, 71, 462-475.	1.9	1,241
3	European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines. <i>European Urology</i> , 2021, 79, 82-104.	1.9	1,152
4	EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2013 Guidelines. <i>European Urology</i> , 2014, 65, 778-792.	1.9	868
5	An Individual Patient Data Meta-Analysis of the Long-Term Outcome of Randomised Studies Comparing Intravesical Mitomycin C versus Bacillus Calmette-Guérin for Non-muscle-Invasive Bladder Cancer. <i>European Urology</i> , 2009, 56, 247-256.	1.9	527
6	Accuracy of Magnetic Resonance Imaging for Local Staging of Prostate Cancer: A Diagnostic Meta-analysis. <i>European Urology</i> , 2016, 70, 233-245.	1.9	466
7	Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma. <i>New England Journal of Medicine</i> , 2021, 384, 2102-2114.	27.0	427
8	Photodynamic Diagnosis of Non-muscle-invasive Bladder Cancer with Hexaminolevulinate Cystoscopy: A Meta-analysis of Detection and Recurrence Based on Raw Data. <i>European Urology</i> , 2013, 64, 846-854.	1.9	372
9	Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical) Tj ETQq1 1 0.784314 rgBT / Over	1.9	372
10	Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ MO urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2015, 16, 76-86.	10.7	323
11	Long-term Cancer-specific Survival in Patients with High-risk, Non-muscle-invasive Bladder Cancer and Tumour Progression: A Systematic Review. <i>European Urology</i> , 2011, 60, 493-500.	1.9	274
12	Use of the Prostate Imaging Reporting and Data System (PI-RADS) for Prostate Cancer Detection with Multiparametric Magnetic Resonance Imaging: A Diagnostic Meta-analysis. <i>European Urology</i> , 2015, 67, 1112-1121.	1.9	270
13	A Review of Current Guidelines and Best Practice Recommendations for the Management of Nonmuscle Invasive Bladder Cancer by the International Bladder Cancer Group. <i>Journal of Urology</i> , 2011, 186, 2158-2167.	0.4	247
14	European Association of Urology Guidelines Office Rapid Reaction Group: An Organisation-wide Collaborative Effort to Adapt the European Association of Urology Guidelines Recommendations to the Coronavirus Disease 2019 Era. <i>European Urology</i> , 2020, 78, 21-28.	1.9	239
15	Prognosis of Muscle-Invasive Bladder Cancer: Difference between Primary and Progressive Tumours and Implications for Therapy. <i>European Urology</i> , 2004, 45, 292-296.	1.9	235
16	Economic Burden of Bladder Cancer Across the European Union. <i>European Urology</i> , 2016, 69, 438-447.	1.9	223
17	Hexyl Aminolevulinat-Guided Fluorescence Cystoscopy in the Diagnosis and Follow-up of Patients with Non-muscle-invasive Bladder Cancer: A Critical Review of the Current Literature. <i>European Urology</i> , 2013, 64, 624-638.	1.9	193
18	Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-muscle-invasive Bladder Cancer. <i>European Urology</i> , 2016, 69, 1046-1052.	1.9	176

#	ARTICLE	IF	CITATIONS
19	Cost-effectiveness of Magnetic Resonance (MR) Imaging and MR-guided Targeted Biopsy Versus Systematic Transrectal Ultrasound-Guided Biopsy in Diagnosing Prostate Cancer: A Modelling Study from a Health Care Perspective. <i>European Urology</i> , 2014, 66, 430-436.	1.9	171
20	The Role of a Combined Regimen With Intravesical Chemotherapy and Hyperthermia in the Management of Non-muscle-invasive Bladder Cancer: A Systematic Review. <i>European Urology</i> , 2011, 60, 81-93.	1.9	166
21	The Impact of the Extent of Lymphadenectomy on Oncologic Outcomes in Patients Undergoing Radical Cystectomy for Bladder Cancer: A Systematic Review. <i>European Urology</i> , 2014, 66, 1065-1077.	1.9	164
22	The Schedule and Duration of Intravesical Chemotherapy in Patients with Non-Muscle-Invasive Bladder Cancer: A Systematic Review of the Published Results of Randomized Clinical Trials. <i>European Urology</i> , 2008, 53, 709-719.	1.9	162
23	Long-Term Decrease in Bladder Cancer Recurrence with Hexaminolevulinat Enabled Fluorescence Cystoscopy. <i>Journal of Urology</i> , 2012, 188, 58-62.	0.4	158
24	The 2021 Updated European Association of Urology Guidelines on Metastatic Urothelial Carcinoma. <i>European Urology</i> , 2022, 81, 95-103.	1.9	158
25	European genome-wide association study identifies SLC14A1 as a new urinary bladder cancer susceptibility gene. <i>Human Molecular Genetics</i> , 2011, 20, 4268-4281.	2.9	134
26	Fast dynamic gadolinium-enhanced MR imaging of urinary bladder and prostate cancer. <i>Journal of Magnetic Resonance Imaging</i> , 1999, 10, 295-304.	3.4	133
27	EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer: An International Collaborative Multistakeholder Effort. <i>European Urology</i> , 2020, 77, 223-250.	1.9	132
28	Intravesical Pharmacotherapy for Non-Muscle-Invasive Bladder Cancer: A Critical Analysis of Currently Available Drugs, Treatment Schedules, and Long-Term Results. <i>European Urology</i> , 2008, 53, 45-52.	1.9	127
29	Original Articles: Bladder Cancer: A Randomized Study of Intravesical Mitomycin C, Bacillus Calmette-Guerin Tice and Bacillus Calmette-Guerin RIVM Treatment in pTa-pT1 Papillary Carcinoma and Carcinoma in Situ of the Bladder. <i>Journal of Urology</i> , 1995, 153, 929-933.	0.4	123
30	Hexaminolevulinat-Guided Fluorescence Cystoscopy in the Diagnosis and Follow-Up of Patients with Non-Muscle-Invasive Bladder Cancer: Review of the Evidence and Recommendations. <i>European Urology</i> , 2010, 57, 607-614.	1.9	117
31	Predicting Response to Intravesical Bacillus Calmette-Guérin Immunotherapy: Are We There Yet? A Systematic Review. <i>European Urology</i> , 2018, 73, 738-748.	1.9	112
32	Combined Thermo-Chemotherapy for Recurrent Bladder Cancer After Bacillus Calmette-Guerin. <i>Journal of Urology</i> , 2009, 182, 1313-1317.	0.4	109
33	BCG-unresponsive non-muscle-invasive bladder cancer: recommendations from the IBCG. <i>Nature Reviews Urology</i> , 2017, 14, 244-255.	3.8	108
34	The role of hexaminolevulinat fluorescence cystoscopy in bladder cancer. <i>Nature Reviews Urology</i> , 2007, 4, 542-549.	1.4	103
35	Intravesical hyperthermia and mitomycin-C for carcinoma in situ of the urinary bladder: experience of the European Synergo working party. <i>World Journal of Urology</i> , 2009, 27, 319-324.	2.2	98
36	Defining Progression in Nonmuscle Invasive Bladder Cancer: It is Time for a New, Standard Definition. <i>Journal of Urology</i> , 2014, 191, 20-27.	0.4	98

#	ARTICLE	IF	CITATIONS
37	Performance of the Bladder EpiCheck [®] , a Methylation Test for Patients Under Surveillance for Non-muscle-invasive Bladder Cancer: Results of a Multicenter, Prospective, Blinded Clinical Trial. <i>European Urology Oncology</i> , 2018, 1, 307-313.	5.4	92
38	What Is the Prognostic and Clinical Importance of Urothelial and Nonurothelial Histological Variants of Bladder Cancer in Predicting Oncological Outcomes in Patients with Muscle-invasive and Metastatic Bladder Cancer? A European Association of Urology Muscle Invasive and Metastatic Bladder Cancer Guidelines Panel Systematic Review. <i>European Urology Oncology</i> , 2019, 2, 625-642.	5.4	88
39	Current clinical practice gaps in the treatment of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) with emphasis on the use of bacillus Calmette-Guérin (BCG): results of an international individual patient data survey (IPDS). <i>BJU International</i> . 2013. 112. 742-750.	2.5	87
40	Defining and Treating the Spectrum of Intermediate Risk Nonmuscle Invasive Bladder Cancer. <i>Journal of Urology</i> , 2014, 192, 305-315.	0.4	82
41	100 years of Bacillus Calmette-Guérin immunotherapy: from cattle to COVID-19. <i>Nature Reviews Urology</i> , 2021, 18, 611-622.	3.8	80
42	Comparison of Hexaminolevulinate Based Flexible and Rigid Fluorescence Cystoscopy with Rigid White Light Cystoscopy in Bladder Cancer: Results of a Prospective Phase II Study. <i>European Urology</i> , 2005, 47, 319-322.	1.9	75
43	Clinical and Cost Effectiveness of Hexaminolevulinate-guided Blue-light Cystoscopy: Evidence Review and Updated Expert Recommendations. <i>European Urology</i> , 2014, 66, 863-871.	1.9	72
44	Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naïve castration-resistant prostate cancer. , 2019, 7, 302.		72
45	Hexaminolevulinate blue-light cystoscopy in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on appropriate use in the USA. <i>Nature Reviews Urology</i> , 2014, 11, 589-596.	3.8	69
46	The Effect of Age on the Efficacy of Maintenance Bacillus Calmette-Guérin Relative to Maintenance Epirubicin in Patients with Stage Ta T1 Urothelial Bladder Cancer: Results from EORTC Genito-Urinary Group Study 30911. <i>European Urology</i> , 2014, 66, 694-701.	1.9	68
47	Prospective Validation of an mRNA-based Urine Test for Surveillance of Patients with Bladder Cancer. <i>European Urology</i> , 2019, 75, 853-860.	1.9	68
48	Phase II Marker Lesion Study With Intravesical Instillation of Apaziquone for Superficial Bladder Cancer: Toxicity and Marker Response. <i>Journal of Urology</i> , 2006, 176, 1349-1353.	0.4	67
49	Comparison of Three Schedules of Intravesical Epirubicin in Patients with Non-muscle-Invasive Bladder Cancer. <i>European Urology</i> , 2008, 53, 984-991.	1.9	67
50	Treatment Options Available for Bacillus Calmette-Guérin Failure in Non-muscle-invasive Bladder Cancer. <i>European Urology</i> , 2012, 62, 1088-1096.	1.9	67
51	A five-gene expression signature to predict progression in T1G3 bladder cancer. <i>European Journal of Cancer</i> , 2016, 64, 127-136.	2.8	67
52	Diagnostic accuracy, clinical utility and influence on decision-making of a methylation urine biomarker test in the surveillance of non-muscle-invasive bladder cancer. <i>BJU International</i> , 2019, 123, 959-967.	2.5	63
53	Therapeutic Options in High-risk Non-muscle-invasive Bladder Cancer During the Current Worldwide Shortage of Bacille Calmette-Guérin. <i>European Urology</i> , 2015, 67, 359-360.	1.9	62
54	The Importance of Hospital and Surgeon Volume as Major Determinants of Morbidity and Mortality After Radical Cystectomy for Bladder Cancer: A Systematic Review and Recommendations by the European Association of Urology Muscle-invasive and Metastatic Bladder Cancer Guideline Panel. <i>European Urology Oncology</i> , 2020, 3, 131-144.	5.4	61

#	ARTICLE	IF	CITATIONS
55	Fluorescence and white light cystoscopy for detection of carcinoma in situ of the urinary bladder. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2012, 30, 285-289.	1.6	60
56	Measuring health-related quality of life in men with prostate cancer: A systematic review of the most used questionnaires and their validity. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 69.e19-69.e28.	1.6	58
57	Results of the European Basic Laparoscopic Urological Skills Examination. <i>European Urology</i> , 2014, 65, 490-496.	1.9	56
58	Combined Chemohyperthermia: 10-Year Single Center Experience in 160 Patients with Nonmuscle Invasive Bladder Cancer. <i>Journal of Urology</i> , 2014, 192, 708-713.	0.4	56
59	The efficacy of BCG TICE and BCG Connaught in a cohort of 2,099 patients with T1G3 non-muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 484.e19-484.e25.	1.6	53
60	Lutetium-177-PSMA-617 in Low-Volume Hormone-Sensitive Metastatic Prostate Cancer: A Prospective Pilot Study. <i>Clinical Cancer Research</i> , 2021, 27, 3595-3601.	7.0	53
61	Genome-wide association study yields variants at 20p12.2 that associate with urinary bladder cancer. <i>Human Molecular Genetics</i> , 2014, 23, 5545-5557.	2.9	46
62	The Impact of Blue Light Cystoscopy with Hexaminolevulinat (HAL) on Progression of Bladder Cancer – A New Analysis. <i>Bladder Cancer</i> , 2016, 2, 273-278.	0.4	46
63	MRI-guided focal laser ablation for prostate cancer followed by radical prostatectomy: correlation of treatment effects with imaging. <i>World Journal of Urology</i> , 2017, 35, 703-711.	2.2	42
64	Intracutaneous and Intravesical Immunotherapy With Keyhole Limpet Hemocyanin Compared With Intravesical Mitomycin in Patients With Non-muscle-Invasive Bladder Cancer: Results From a Prospective Randomized Phase III Trial. <i>Journal of Clinical Oncology</i> , 2012, 30, 2273-2279.	1.6	41
65	Interferon alfa in the treatment paradigm for non-muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 35.e21-35.e30.	1.6	40
66	Diagnostic Accuracy of Novel Urinary Biomarker Tests in Non-muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis. <i>European Urology Oncology</i> , 2021, 4, 927-942.	5.4	40
67	Discrepancy between clinical staging through bimanual palpation and pathological staging after cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2012, 30, 247-251.	1.6	39
68	Does a decision aid for prostate cancer affect different aspects of decisional regret, assessed with new regret scales? A randomized, controlled trial. <i>Health Expectations</i> , 2016, 19, 459-470.	2.6	39
69	Prediction model for recurrence probabilities after intravesical chemotherapy in patients with intermediate-risk non-muscle-invasive bladder cancer, including external validation. <i>World Journal of Urology</i> , 2016, 34, 173-180.	2.2	37
70	Evaluating F-18-PSMA-1007-PET in primary prostate cancer and comparing it to multi-parametric MRI and histopathology. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 423-430.	3.9	37
71	Intra-therapeutic dosimetry of [177Lu]Lu-PSMA-617 in low-volume hormone-sensitive metastatic prostate cancer patients and correlation with treatment outcome. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 460-469.	6.4	36
72	Two-year follow-up of the phase II marker lesion study of intravesical apaziquone for patients with non-muscle invasive bladder cancer. <i>World Journal of Urology</i> , 2009, 27, 337-342.	2.2	35

#	ARTICLE	IF	CITATIONS
73	Results of a Phase 1 Dose Escalation Study of Intravesical TMX-101 in Patients with Nonmuscle Invasive Bladder Cancer. <i>Journal of Urology</i> , 2013, 189, 2077-2082.	0.4	35
74	The effect of smoking and timing of smoking cessation on clinical outcome in non-muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 65.e9-65.e17.	1.6	35
75	Performance of Narrow Band Imaging (NBI) and Photodynamic Diagnosis (PDD) Fluorescence Imaging Compared to White Light Cystoscopy (WLC) in Detecting Non-Muscle Invasive Bladder Cancer: A Systematic Review and Lesion-Level Diagnostic Meta-Analysis. <i>Cancers</i> , 2021, 13, 4378.	3.7	35
76	Quality Indicators for Bladder Cancer Services: A Collaborative Review. <i>European Urology</i> , 2020, 78, 43-59.	1.9	34
77	Body Mass Index, Diet-Related Factors, and Bladder Cancer Prognosis: A Systematic Review and Meta-Analysis. <i>Bladder Cancer</i> , 2018, 4, 91-112.	0.4	33
78	Lutetium-177-PSMA-Targeted as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trial. <i>BMC Cancer</i> , 2020, 20, 884.	2.6	32
79	Robot-assisted Radical Cystectomy Versus Open Radical Cystectomy in Bladder Cancer Patients: A Multicentre Comparative Effectiveness Study. <i>European Urology</i> , 2021, 79, 609-618.	1.9	32
80	Blue-light cystoscopy in the evaluation of non-muscle-invasive bladder cancer. <i>Therapeutic Advances in Urology</i> , 2014, 6, 25-33.	2.0	31
81	LINC expression predicts and mediates the response to platinum-based chemotherapy in muscle-invasive bladder cancer. <i>Cancer Medicine</i> , 2018, 7, 3342-3350.	2.8	31
82	ICUD-SIU International Consultation on Bladder Cancer 2017: management of non-muscle invasive bladder cancer. <i>World Journal of Urology</i> , 2019, 37, 51-60.	2.2	31
83	Risk-adapted management of low-grade bladder tumours: recommendations from the International Bladder Cancer Group (IBCG). <i>BJU International</i> , 2020, 125, 497-505.	2.5	31
84	International Bladder Cancer Group Consensus Statement on Clinical Trial Design for Patients with Bacillus Calmette-Guérin-exposed High-risk Non-muscle-invasive Bladder Cancer. <i>European Urology</i> , 2022, 82, 34-46.	1.9	30
85	Follow-up of patients after curative bladder cancer treatment: guidelines vs. practice. <i>Current Opinion in Urology</i> , 2010, 20, 437-442.	1.8	28
86	Increasing age is not associated with toxicity leading to discontinuation of treatment in patients with urothelial non-muscle-invasive bladder cancer randomised to receive 3 years of maintenance bacille Calmette-Guérin: results from European Organisation for Research and Treatment of Cancer Genito-Urinary Group study 30911. <i>BJU International</i> , 2016, 118, 423-428.	2.5	28
87	Platinum exposure and cause-specific mortality among patients with testicular cancer. <i>Cancer</i> , 2020, 126, 628-639.	4.1	28
88	Diagnostic Accuracy of MCM5 for the Detection of Recurrence in Nonmuscle Invasive Bladder Cancer Followup: A Blinded, Prospective Cohort, Multicenter European Study. <i>Journal of Urology</i> , 2020, 204, 685-690.	0.4	28
89	Location of Prostate Cancers Determined by Multiparametric and MRI-Guided Biopsy in Patients With Elevated Prostate-Specific Antigen Level and at Least One Negative Transrectal Ultrasound-Guided Biopsy. <i>American Journal of Roentgenology</i> , 2015, 205, 57-63.	2.2	26
90	Evidence-based Assessment of Current and Emerging Bladder-sparing Therapies for Non-muscle-invasive Bladder Cancer After Bacillus Calmette-Guérin Therapy: A Systematic Review and Meta-analysis. <i>European Urology Oncology</i> , 2020, 3, 318-340.	5.4	26

#	ARTICLE	IF	CITATIONS
91	A short-term intervention with selenium affects expression of genes implicated in the epithelial-to-mesenchymal transition in the prostate. <i>Oncotarget</i> , 2017, 8, 10565-10579.	1.8	26
92	Clinical Validation of a Urine Test (Uromonitor-V2 [®]) for the Surveillance of Non-Muscle-Invasive Bladder Cancer Patients. <i>Diagnostics</i> , 2020, 10, 745.	2.6	25
93	Validation of an mRNA-based Urine Test for the Detection of Bladder Cancer in Patients with Haematuria. <i>European Urology Oncology</i> , 2021, 4, 93-101.	5.4	25
94	[⁶⁸ Ga]Ga-PSMA-11 PET imaging as a predictor for absorbed doses in organs at risk and small lesions in [¹⁷⁷ Lu]Lu-PSMA-617 treatment. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 1101-1112.	6.4	25
95	Independent Replication of Published Germline Polymorphisms Associated with Urinary Bladder Cancer Prognosis and Treatment Response. <i>Bladder Cancer</i> , 2016, 2, 77-89.	0.4	24
96	Value of Serial Multiparametric Magnetic Resonance Imaging and Magnetic Resonance Imaging-guided Biopsies in Men with Low-risk Prostate Cancer on Active Surveillance After 1 Yr Follow-up. <i>European Urology Focus</i> , 2019, 5, 407-415.	3.1	23
97	Multiparametric Magnetic Resonance Imaging Should Be Preferred Over Digital Rectal Examination for Prostate Cancer Local Staging and Disease Risk Classification. <i>Urology</i> , 2021, 147, 205-212.	1.0	23
98	Intravesical Radiofrequency-Induced Chemohyperthermia for Carcinoma in Situ of the Urinary Bladder: A Retrospective Multicentre Study. <i>Bladder Cancer</i> , 2018, 4, 365-376.	0.4	22
99	Current Recommendations for the Management of Bladder Cancer. <i>Drugs</i> , 1997, 53, 404-414.	10.9	21
100	Evaluation of an orthotopic rat bladder urothelial cell carcinoma model by cystoscopy. <i>BJU International</i> , 2008, 101, 889-893.	2.5	21
101	Comparison of the performances of the ADXBLADDER test and urinary cytology in the follow-up of non-muscle-invasive bladder cancer: a blinded prospective multicentric study. <i>BJU International</i> , 2021, 127, 198-204.	2.5	21
102	Perioperative pembrolizumab therapy in muscle-invasive bladder cancer: Phase III KEYNOTE-866 and KEYNOTE-905/EV-303. <i>Future Oncology</i> , 2021, 17, 3137-3150.	2.4	21
103	Follow-up in non-muscle invasive bladder cancer: facts and future. <i>World Journal of Urology</i> , 2021, 39, 4047-4053.	2.2	21
104	A cost-effectiveness modeling study of robot-assisted (RARC) versus open radical cystectomy (ORC) for bladder cancer to inform future research. <i>European Urology Focus</i> , 2019, 5, 1058-1065.	3.1	20
105	Prognostic Relevance of Urinary Bladder Cancer Susceptibility Loci. <i>PLoS ONE</i> , 2014, 9, e89164.	2.5	20
106	Impact of DNA damage repair defects on response to PSMA radioligand therapy in metastatic castration-resistant prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 71-78.	3.9	19
107	Safety of Hexaminolevulinatate for Blue Light Cystoscopy in Bladder Cancer. A Combined Analysis of the Trials Used for Registration and Postmarketing Data. <i>Urology</i> , 2014, 84, 122-126.	1.0	18
108	Intermediate-risk Non-muscle-invasive Bladder Cancer: Updated Consensus Definition and Management Recommendations from the International Bladder Cancer Group. <i>European Urology Oncology</i> , 2022, 5, 505-516.	5.4	18

#	ARTICLE	IF	CITATIONS
109	Pharmacokinetic, Pharmacodynamic, and Activity Evaluation of TMX-101 in a Multicenter Phase 1 Study in Patients With Papillary Non-Muscle-Invasive Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 204-209.e2.	1.9	17
110	DPPG2-Based Thermosensitive Liposomes with Encapsulated Doxorubicin Combined with Hyperthermia Lead to Higher Doxorubicin Concentrations in the Bladder Compared to Conventional Application in Pigs: A Rationale for the Treatment of Muscle-Invasive Bladder Cancer. <i>International Journal of Nanomedicine</i> , 2021, Volume 16, 75-88.	6.7	17
111	Learning Curve Analysis for Intracorporeal Robot-assisted Radical Cystectomy: Results from the EAU Robotic Urology Section Scientific Working Group. <i>European Urology Open Science</i> , 2022, 39, 55-61.	0.4	17
112	Apaziquone for non-muscle invasive bladder cancer: a critical review. <i>Expert Opinion on Investigational Drugs</i> , 2008, 17, 1085-1096.	4.1	15
113	Dose-Dependent Effect of Platinum-Based Chemotherapy on the Risk of Metachronous Contralateral Testicular Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 319-327.	1.6	15
114	Radical Cystectomy in a Dutch University Hospital: Long-Term Outcomes and Prognostic Factors in a Homogeneous Surgery-Only Series. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 190-195.	1.9	14
115	Intravesical radiofrequency induced hyperthermia enhances mitomycin C accumulation in tumour tissue. <i>International Journal of Hyperthermia</i> , 2018, 34, 988-993.	2.5	14
116	Risk of diabetes after para-aortic radiation for testicular cancer. <i>British Journal of Cancer</i> , 2018, 119, 901-907.	6.4	14
117	Assessment of the efficacy of repeated instillations of mitomycin C mixed with a thermosensitive hydrogel in an orthotopic rat bladder cancer model. <i>Therapeutic Advances in Urology</i> , 2018, 10, 213-221.	2.0	14
118	Intravesical Chemohyperthermia vs. Bacillus Calmette-Guerin Instillation for Intermediate- and High-Risk Non-muscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis. <i>Frontiers in Surgery</i> , 2021, 8, 775527.	1.4	14
119	The UroLife study: protocol for a Dutch prospective cohort on lifestyle habits in relation to non-muscle-invasive bladder cancer prognosis and health-related quality of life. <i>BMJ Open</i> , 2019, 9, e030396.	1.9	13
120	Long-Term Experience with Radiofrequency-Induced Hyperthermia Combined with Intravesical Chemotherapy for Non-Muscle Invasive Bladder Cancer. <i>Cancers</i> , 2021, 13, 377.	3.7	13
121	Update to a randomized controlled trial of lutetium-177-PSMA in Oligo-metastatic hormone-sensitive prostate cancer: the BULLSEYE trial. <i>Trials</i> , 2021, 22, 768.	1.6	13
122	Improving indication, technique and outcome of radical cystectomy. <i>Nature Reviews Urology</i> , 2016, 13, 74-76.	3.8	12
123	Identification of long non-coding RNAs that stimulate cell survival in bladder cancer. <i>Oncotarget</i> , 2017, 8, 34442-34452.	1.8	12
124	Active Surveillance for Prostate Cancer in a Real-life Cohort: Comparing Outcomes for PRIAS-eligible and PRIAS-ineligible Patients. <i>European Urology Oncology</i> , 2018, 1, 231-237.	5.4	11
125	Impact of the COVID-19 outbreak on prostate cancer care in the Netherlands. <i>Cancer Treatment and Research Communications</i> , 2022, 31, 100553.	1.7	11
126	Urinary cytokines in patients treated with intravesical mitomycin-C with and without hyperthermia. <i>World Journal of Urology</i> , 2015, 33, 1411-1417.	2.2	10

#	ARTICLE	IF	CITATIONS
127	Double-Blind, Randomized, Placebo-controlled Studies Evaluating Apaziquone (E09, Qapzolaâ„¢) Intravesical Instillation Post Transurethral Resection of Bladder Tumors for the Treatment of Low-risk Non-Muscle Invasive Bladder Cancer. <i>Bladder Cancer</i> , 2018, 4, 293-301.	0.4	10
128	External validation of the Memorial Sloan Kettering Cancer Centre and Briganti nomograms for the prediction of lymph node involvement of prostate cancer using clinical stage assessed by magnetic resonance imaging. <i>BJU International</i> , 2021, 128, 236-243.	2.5	10
129	Circulating tumour cells to drive the use of neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer. <i>ESMO Open</i> , 2022, 7, 100416.	4.5	10
130	The effect of photochemical internalization of bleomycin in the treatment of urothelial carcinoma of the bladder: An in vitro study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 49.e1-49.e6.	1.6	9
131	Management of Low-risk and Intermediate-risk Non-muscle-invasive Bladder Carcinoma. <i>Hematology/Oncology Clinics of North America</i> , 2015, 29, 219-225.	2.2	9
132	Translation and validation of two disease-specific patient-reported outcome measures (Bladder) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 54 Outcomes, 2019, 3, 62.	1.9	9
133	Reducing the Frequency of Follow-up Cystoscopy in Low-grade pTa Non-muscle-invasive Bladder Cancer Using the ADXBLADDER Biomarker. <i>European Urology Focus</i> , 2022, 8, 1643-1649.	3.1	9
134	MULTIFOCAL TRANSITIONAL CELL CANCER AND p53 MUTATION ANALYSIS. <i>Journal of Urology</i> , 1998, 160, 124-125.	0.4	8
135	Pharmacokinetics and toxicity of intravesical TMX-101: a preclinical study in pigs. <i>BJU International</i> , 2011, 108, 1210-1214.	2.5	7
136	A placebo-controlled efficacy study of the intravesical immunomodulators TMX-101 and TMX-202 in an orthotopic bladder cancer rat model. <i>World Journal of Urology</i> , 2018, 36, 1719-1725.	2.2	7
137	Follow-up in Active Surveillance for Prostate Cancer: Strict Protocol Adherence Remains Important for PRIAS-ineligible Patients. <i>European Urology Oncology</i> , 2019, 2, 483-489.	5.4	7
138	Follow-up of the Urethra and Management of Urethral Recurrence After Radical Cystectomy: A Systematic Review and Proposal of Management Algorithm by the European Association of Urology Young Academic Urologists: Urothelial Carcinoma Working Group. <i>European Urology Focus</i> , 2022, 8, 1635-1642.	3.1	7
139	Management of the first recurrence of T1G3 bladder cancer: Does intravesical chemotherapy deserve a chance?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2009, 27, 322-324.	1.6	6
140	Thermo Reversible Hydrogel Based Delivery of Mitomycin C (UGN-101) for Treatment of Upper Tract Urothelial Carcinoma (UTUC). <i>Bladder Cancer</i> , 2019, 5, 21-29.	0.4	6
141	Vesical Imaging-Reporting and Data System (VI-RADS) for Bladder Cancer Diagnostics: The Replacement for Surgery?. <i>European Urology Oncology</i> , 2020, 3, 316-317.	5.4	6
142	Robot-assisted Versus Open Radical Cystectomy in Bladder Cancer: An Economic Evaluation Alongside a Multicentre Comparative Effectiveness Study. <i>European Urology Focus</i> , 2022, 8, 739-747.	3.1	6
143	Limited Changes in Lifestyle Behaviours after Non-Muscle Invasive Bladder Cancer Diagnosis. <i>Cancers</i> , 2022, 14, 960.	3.7	6
144	Validation and reliability of the Dutch version of the EORTC QLQ-NMIBC24 Questionnaire Module for patients with non-muscle-invasive bladder cancer. <i>Journal of Patient-Reported Outcomes</i> , 2021, 5, 96.	1.9	5

#	ARTICLE	IF	CITATIONS
145	The safety, tolerability, and efficacy of a neoadjuvant gemcitabine intravesical drug delivery system (TAR-200) in muscle-invasive bladder cancer patients: a phase I trial. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 344.e1-344.e9.	1.6	5
146	Expert review: an update in current and developing intravesical therapies for non-muscle-invasive bladder cancer. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 1257-1268.	2.4	4
147	Do Orthotopic Ileal Diversions Induce Immunological Changes in Retained Urethral Tissue?. <i>Bladder Cancer</i> , 2015, 1, 97-103.	0.4	4
148	High Health-Related Quality of Life During Dendritic Cell Vaccination Therapy in Patients With Castration-Resistant Prostate Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 536700.	2.8	4
149	Hospital volume is associated with postoperative mortality after radical cystectomy for treatment of bladder cancer. <i>BJU International</i> , 2021, 128, 511-518.	2.5	4
150	Organ-Sparing Strategies in Muscle-Invasive Bladder Cancer. <i>Cancer Management and Research</i> , 2021, Volume 13, 7833-7839.	1.9	4
151	The conundrum of recurrent low-grade tumours. <i>Current Opinion in Urology</i> , 2018, 28, 557-562.	1.8	3
152	Radiofrequency-induced Thermochemotherapy for Recurrent Non-muscle-invasive Bladder Cancer: A New Treatment for an Unmet Need?. <i>European Urology</i> , 2019, 75, 72-73.	1.9	3
153	Developments in the follow-up of nonmuscle invasive bladder cancer. <i>Current Opinion in Urology</i> , 2020, 30, 387-391.	1.8	3
154	Cutting-edge Management of Muscle-invasive Bladder Cancer in 2020 and a Glimpse into the Future. <i>European Urology Oncology</i> , 2020, 3, 789-801.	5.4	3
155	DPPG2-based thermosensitive liposomes as drug delivery system for effective muscle-invasive bladder cancer treatment in vivo. <i>International Journal of Hyperthermia</i> , 2021, 38, 1415-1424.	2.5	3
156	A Systematic Review of Outcome Reporting, Definition and Measurement Heterogeneity in Non-Muscle Invasive Bladder Cancer Effectiveness Trials of Adjuvant, Prophylactic Treatment After Transurethral Resection. <i>Bladder Cancer</i> , 2021, 7, 221-241.	0.4	3
157	Non-metastatic muscle-invasive bladder cancer: the role of age in receiving treatment with curative intent. <i>BJU International</i> , 2022, 130, 764-775.	2.5	3
158	Reply to Sarah Willis, Alec Miners, and Jan van der Meulen's Letter to the Editor re: Maarten de Rooij, Simone Crienen, J. Alfred Witjes, Jelle O. Barentsz, Maroeska M. Rovers, Janneke P.C. Grutters. Cost-effectiveness of Magnetic Resonance (MR) Imaging and MR-guided Targeted Biopsy Versus Systematic Transrectal Ultrasound-guided Biopsy in Diagnosing Prostate Cancer: A Modelling Study from a Health Care Perspective. <i>Eur Urol</i> . In press. http://dx.doi.org/10.1016/j.eururo.2013.12.012 .	1.9	2
159	Fluorescence cystoscopy: the end of biopsies for carcinoma in situ detection?. <i>BJU International</i> , 2015, 116, 2-3.	2.5	2
160	Adjuvant recMAGE-A3 Immunotherapy After Cystectomy for Muscle-invasive Bladder Cancer: Lessons Learned from the Phase 2 MAGNOLIA Clinical Trial. <i>European Urology Focus</i> , 2019, 5, 849-852.	3.1	2
161	Reply to Francesco Montorsi, Marco Bandini, Alberto Briganti, et al. Re-establishing the Role of Robot-assisted Radical Cystectomy After the 2020 EAU Muscle-invasive and Metastatic Bladder Cancer Guideline Panel Recommendations. <i>Eur Urol</i> 2020;78:489-91. <i>European Urology</i> , 2020, 78, 492-493.	1.9	2
162	Hospital-specific probability of cystectomy affects survival from muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 935.e9-935.e16.	1.6	2

#	ARTICLE	IF	CITATIONS
163	Patient-reported outcomes and health-related quality of life after urinary diversions. <i>Current Opinion in Urology</i> , 2021, Publish Ahead of Print, 574-579.	1.8	2
164	Predicting surgical outcome in posterior retroperitoneoscopic adrenalectomy with the aid of a preoperative nomogram. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2022, 36, 6507-6515.	2.4	2
165	Reduced Dose Intravesical Bacillus Calmette-Guérin: Why It Might Not Matter. <i>Bladder Cancer</i> , 2022, 8, 113-117.	0.4	2
166	The impact of the COVID-19 pandemic on bladder cancer care in the Netherlands. <i>Bladder Cancer</i> , 2022, , 1-17.	0.4	2
167	Hexyl Aminolevulinate in the Detection of Bladder Cancer. <i>Drugs</i> , 2006, 66, 579-580.	10.9	1
168	The Final Answer to the Question of Whether We Should Use a Single Postoperative Instillation of Chemotherapy After Resection of pTa and pT1 Bladder Tumors. <i>European Urology</i> , 2016, 69, 245-246.	1.9	1
169	Re: Trends in the Use of Perioperative Chemotherapy for Localized and Locally Advanced Muscle-invasive Bladder Cancer: A Sign of Changing Tides. <i>European Urology</i> , 2016, 69, 963.	1.9	0
170	Reply to Sławomir Poletajew, Piotr Radziszewski, Juan Palou's Letter to the Editor re: Tom J.H. Arends, Ofer Nativ, Massimo Maffezzini, et al. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-muscle-invasive Bladder Cancer. <i>Eur Urol</i> 2016;69:1046-52. <i>European Urology</i> , 2017, 71, e31-e32.	1.9	0
171	Re: Bladder Preservation with Twice-a-day Radiation plus Fluorouracil/Cisplatin or Once Daily Radiation plus Gemcitabine for Muscle-invasive Bladder Cancer: NRG/RTOG 0712: A Randomized Phase II Trial. <i>European Urology</i> , 2019, 75, 1033-1034.	1.9	0
172	Reply to Harshit Garg, Brusabhanu Nayak and Prabhjot Singh's Letter to the Editor Re: Tom J.H. Arends, Ofer Nativ, Massimo Maffezzini, et al. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guerin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-muscle-invasive Bladder Cancer. <i>Eur Urol</i> 2016;69:1046-52. <i>European Urology</i> , 2019, 75, e26.	1.9	0
173	Re: Optimal Cystectomy Outcome: A Composite Measurement Evaluating Quality of Care and Mortality Benefit. <i>European Urology</i> , 2021, 79, 316.	1.9	0
174	Low Risk of Severe Complications After a Single, Post-Operative Instillation of Intravesical Chemotherapy in Patients with TaG1G2 Urothelial Bladder Carcinoma. <i>Bladder Cancer</i> , 2021, 7, 193-203.	0.4	0
175	Re: Five-factor Prognostic Model for Survival of Post-platinum Patients with Metastatic Urothelial Carcinoma Receiving PD-L1 Inhibitors. <i>European Urology</i> , 2021, 80, 113.	1.9	0
176	Device-Assisted Therapies for Nonmuscle-Invasive Bladder Cancer: A Practical Approach. , 2021, , 103-110.		0
177	Value of multimodality MRI and MR-guided biopsy at inclusion in an active surveillance protocol for prostate cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, 105-105.	1.6	0
178	Editorial Comment. <i>Journal of Urology</i> , 2020, 203, 908-909.	0.4	0
179	Use of perioperative treatment (tx) among patients (pts) undergoing radical resection (RR) for muscle-invasive urothelial cancer (MIUC) in France, Germany, Italy, Spain, the United Kingdom, the United States, Canada, China, and Japan.. <i>Journal of Clinical Oncology</i> , 2022, 40, 467-467.	1.6	0
180	Re: Oncological Benefit of Re-resection for T1 Bladder Cancer: A Comparative Effectiveness Study. <i>European Urology</i> , 2022, , .	1.9	0